Discovery of potent, highly selective and orally efficacious SMARCA2 degraders

被引：0
|
作者：
Leng, Lingying
Yang, Lin
Tu, Wenbin
Rej, Rohan
Allu, Srinivasa Rao
Huang, Liyue
Jiang, Wei
Wang, Yu
Stuckey, Jeanne
Sarkari, Farzad R.
Wang, Meilin
Wang, Lu
Wen, Bo
Sun, Duxin
Wang, Shaomeng
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor
    Liddle, John
    Atkinson, Francis L.
    Barker, Michael D.
    Carter, Paul S.
    Curtis, Neil R.
    Davis, Rob P.
    Douault, Clement
    Dickson, Marion C.
    Elwes, Dorothy
    Garton, Neil S.
    Gray, Matthew
    Hayhow, Thomas G.
    Hobbs, Clare I.
    Jones, Emma
    Leach, Stuart
    Leavens, Karen
    Lewis, Huw D.
    McCleary, Scott
    Neu, Margarete
    Patel, Vipulkumar K.
    Preston, Alex G. S.
    Ramirez-Molina, Cesar
    Shipley, Tracy J.
    Skone, Philip A.
    Smithers, Nick
    Somers, Donald O.
    Walker, Ann L.
    Watson, Robert J.
    Weingarten, Gordon G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (20) : 6188 - 6194
  • [22] Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
    Yang, Lin
    Tu, Wenbin
    Huang, Liyue
    Miao, Bukeyan
    Kaneshige, Atsunori
    Jiang, Wei
    Leng, Lingying
    Wang, Meilin
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) : 10761 - 10781
  • [23] Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression
    Zhou, Haibin
    Wu, Dimin
    Bai, Longchuan
    Acharyya, Ranjan K.
    Metwally, Hoda
    McEachern, Donna
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    CANCER RESEARCH, 2024, 84 (06)
  • [24] Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers
    Hulse, Michael
    Elkins, Margot
    Burtell, Jessica
    Vykuntam, Komali
    Vaddi, Kris
    Combs, Andrew
    Ito, Koichi
    Scherle, Peggy
    CANCER RESEARCH, 2023, 83 (07)
  • [25] Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
    Mazan, Andrzej
    Wrobel, Anna
    Dreas, Agnieszka
    Radzimierski, Adam
    Michalik, Kinga
    Kowal, Anna
    Wiklik, Katarzyna
    Wnuk-Lipinska, Katarzyna
    Niedziejko, Paulina
    Kozlowska, Kamila
    Losko, Magdalena
    Szczesniak, Joanna
    Sroka-Porada, Agnieszka
    Martyka, Justyna
    Kulesza, Urszula
    Zuchowicz, Karol
    Zastawna, Magdalena
    Alvarez, Jose
    Stasi, Luigi
    Littlewood, Peter
    Rzymski, Tomasz
    Brzozka, Krzysztof
    CANCER RESEARCH, 2020, 80 (16)
  • [26] GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1
    Taylor, Alexander M.
    Bailey, Chris
    Belmont, Lisa D.
    Campbell, Robert
    Cantone, Nico
    Cote, Alexandre
    Crawford, Terry D.
    Cummings, Richard
    DeMent, Kevin
    Duplessis, Martin
    Flynn, Megan
    Good, Andrew C.
    Huang, Hon-Ren
    Joshi, Shivangi
    Leblanc, Yves
    Murray, Jeremy
    Nasveschuk, Christopher G.
    Neiss, Adrianne
    Poy, Florence
    Romero, F. Anthony
    Sandy, Peter
    Tang, Yong
    Tsui, Vickie
    Zawadzke, Laura
    Sims, Robert J., III
    Audia, James E.
    Bellon, Steven F.
    Magnuson, Steven R.
    Albrecht, Brian K.
    Cochran, Andrea G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11177 - 11186
  • [27] Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
    Thomas, Junius Eugene
    Wang, Mi
    Jiang, Wei
    Wang, Meilin
    Wang, Lu
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8178 - 8199
  • [28] Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers
    Sasmal, Sanjita
    Satyam, Leena K.
    Pothuganti, Manoj K.
    Ettam, Ashokk
    Nunna, Sireesha
    Shareef, Mohammed A.
    Gopinath, Sreevalsam
    Mukherjee, Subhendu
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2018, 78 (13)
  • [29] A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
    Kofink, Christiane
    Trainor, Nicole
    Mair, Barbara
    Woehrle, Simon
    Wurm, Melanie
    Mischerikow, Nikolai
    Roy, Michael J.
    Bader, Gerd
    Greb, Peter
    Garavel, Geraldine
    Diers, Emelyne
    McLennan, Ross
    Whitworth, Claire
    Vetma, Vesna
    Rumpel, Klaus
    Scharnweber, Maximilian
    Fuchs, Julian E.
    Gerstberger, Thomas
    Cui, Yunhai
    Gremel, Gabriela
    Chetta, Paolo
    Hopf, Stefan
    Budano, Nicole
    Rinnenthal, Joerg
    Gmaschitz, Gerhard
    Mayer, Moriz
    Koegl, Manfred
    Ciulli, Alessio
    Weinstabl, Harald
    Farnaby, William
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [30] A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
    Christiane Kofink
    Nicole Trainor
    Barbara Mair
    Simon Wöhrle
    Melanie Wurm
    Nikolai Mischerikow
    Michael J. Roy
    Gerd Bader
    Peter Greb
    Géraldine Garavel
    Emelyne Diers
    Ross McLennan
    Claire Whitworth
    Vesna Vetma
    Klaus Rumpel
    Maximilian Scharnweber
    Julian E. Fuchs
    Thomas Gerstberger
    Yunhai Cui
    Gabriela Gremel
    Paolo Chetta
    Stefan Hopf
    Nicole Budano
    Joerg Rinnenthal
    Gerhard Gmaschitz
    Moriz Mayer
    Manfred Koegl
    Alessio Ciulli
    Harald Weinstabl
    William Farnaby
    Nature Communications, 13
12345